Suppr超能文献

复制压力诱导中期因子表达激活 Notch 信号通路促进胰腺癌上皮间质转化和化疗耐药。

Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer.

机构信息

Department of General-, Visceral- and Thoracic Surgery, Campus Research, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

出版信息

Cancer Res. 2011 Jul 15;71(14):5009-19. doi: 10.1158/0008-5472.CAN-11-0036. Epub 2011 Jun 1.

Abstract

The incidence of pancreatic ductal adenocarcinoma (PDAC) nearly equals its mortality rate, partly because most PDACs are intrinsically chemoresistant and thus largely untreatable. It was found recently that chemoresistant PDAC cells overexpress the Notch-2 receptor and have undergone epithelial-mesenchymal transition (EMT). In this study, we show that these two phenotypes are interrelated by expression of Midkine (MK), a heparin-binding growth factor that is widely overexpressed in chemoresistant PDAC. Gemcitabine, the front-line chemotherapy used in PDAC treatment, induced MK expression in a dose-dependent manner, and its RNAi-mediated depletion was associated with sensitization to gemcitabine treatment. We identified an interaction between the Notch-2 receptor and MK in PDAC cells. MK-Notch-2 interaction activated Notch signaling, induced EMT, upregulated NF-κB, and increased chemoresistance. Taken together, our findings define an important pathway of chemoresistance in PDAC and suggest novel strategies for its clinical attack.

摘要

胰腺导管腺癌 (PDAC) 的发病率几乎与其死亡率相等,部分原因是大多数 PDAC 具有内在的化疗耐药性,因此在很大程度上无法治疗。最近发现,化疗耐药的 PDAC 细胞过度表达 Notch-2 受体,并经历上皮-间充质转化 (EMT)。在这项研究中,我们表明这两种表型通过中期因子 (MK) 的表达相互关联,MK 是一种肝素结合生长因子,在化疗耐药的 PDAC 中广泛过表达。吉西他滨是 PDAC 治疗中使用的一线化疗药物,它以剂量依赖的方式诱导 MK 的表达,而其 RNAi 介导的耗竭与对吉西他滨治疗的敏感性增加相关。我们在 PDAC 细胞中鉴定到 Notch-2 受体和 MK 之间的相互作用。MK-Notch-2 相互作用激活了 Notch 信号通路,诱导 EMT,上调 NF-κB,并增加了化疗耐药性。总之,我们的研究结果定义了 PDAC 中化疗耐药的一个重要途径,并为其临床治疗提供了新的策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验